Status:
COMPLETED
Interest of Concentrations in Meconium of Buprenorphine and Methadone as a Prognostic Factor of NAS Outcome
Lead Sponsor:
University Hospital, Caen
Conditions:
Neonatal Abstinence Syndrome
Eligibility:
FEMALE
18+ years
Brief Summary
The aim of this study is to characterize the interest of concentrations in meconium of drugs used for treatment of pregnant opioid-dependent woman as a prognostic factor of time, severity and duration...
Eligibility Criteria
Inclusion
- Aged over 18 years
- pregnant women
- Having agreed to participate in the study after information
- Under opioid replacement therapy during pregnancy, in combination or not with other psychotropic drugs or legal or illegal substances.
- Delivery after more than 34 weeks of amenorrhea
Exclusion
- Pregnant women not receiving substitution treatment (methadone or buprenorphine).
- Patient under substitution treatment delivering before 34 weeks of amenorrhea
- Patient aged under 18 yrs old
- Patient unable to understand the study (mental deficiency, impairment of consciousness, not French) or not accepting to answer the questionnaires.
- Severe malformation syndrome or chromosomal abnormality in newborn discovered during pregnancy.
- mother's death or newborn's death
Key Trial Info
Start Date :
July 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT03334981
Start Date
July 1 2012
End Date
July 1 2015
Last Update
November 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Caen University Hospital
Caen, France